Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Patheon Directors Win One Court Battle, Plan Another Against JLL

By Pharmaceutical Processing | May 19, 2009

Directors of Patheon have decided to launch legal action against a subsidiary of JLL Partners, in the latest effort to prevent the New York investment firm from gaining control of the pharmaceutical manufacturer. The company announced its plan Tuesday after the Ontario Superior Court ruled against JLL’s effort to block expansion of the membership and mandate of a special committee of directors at Patheon Inc. The committee has urged shareholders to reject an offer of $2 per Patheon share from JLL Patheon Holdings LLC, and the two sides have battled for months in the courts and at the Ontario Securities Commission. On Thursday, Patheon announced that newly elected directors G. Wesley Voorheis and Roy T. Graydon would join an expanded special committee, which would include all directors except JLL’s representatives. JLL asked the court Friday to block that move. The committee has argued JLL’s offer is inadequate. It has also been trying to avoid a “creeping takeover” in which effective control of the board could swing to JLL without a clear majority of shareholders accepting the offer. The committee wants the deadline for JLL’s offer to be extended beyond 6 p.m. ET on Tuesday. “The special committee continues to defend the best interests of all Patheon shareholders. In court, we successfully argued against JLL’s coercive attempt to curtail the activities of the committee,” said Paul Currie, chairman of the special committee. “Shareholders can be assured that the Special Committee is in no way intimidated by JLL’s tactics as it attempts to pursue various avenues to take control of Patheon at an inadequate price. We will take all responsible and appropriate actions, including litigation, to protect Patheon shareholders.” JLL has argued its offer is fair and provides an opportunity for Patheon’s shareholders to get out of a thinly traded stock. It has also taken several steps to rework the offer in accordance with the OSC’s requirements.

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Wyzo
Wyzo high-speed pick-and-place sidebot wins design awards
Purdue University
Purdue University launches institute for advanced manufacturing of pharmaceuticals

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards